Forecasts of Consolidated Financial Results for FY2026
Released on May 11, 2026
| Millions of yen |
FY2025 Actual |
FY2026 Forecast |
YOY Actual |
YOY % |
| Net Sales |
71,127 |
73,000 |
1,872 |
2.6% |
| Operating profit |
5,834 |
6,200 |
365 |
6.3% |
| Ordinary profit |
5,665 |
6,100 |
434 |
7.7% |
| Profit attributable to owners of parent |
5,424 |
4,800 |
(624) |
(11.5)% |
Overview of Earnings Forecast
In the Medium-Term Management Plan 2025, the Group set out to become a "a total healthcare company with a
strong foundation as a specialty pharma company," and achieved its final-year targets in FY2025: net sales of 70
billion yen, an operating profit margin of 8%, and ROE of 8%.The Company is expanding its revenue base and
building a foundation for future growth by strengthening its business foundation, primarily in the obstetrics and
gynecology field, growing key products, and advancing overseas expansion.
In addition, the Group has formulated its long-term vision, "ASKA VISION 2035," and launched the medium-term
management plan 2028, which begins in FY2026. Based on its domestic pharmaceutical business as a foundation,
the Company will promote growth in its drug discovery, global, animal health, and diagnostic/around-the-pill
businesses, while expanding its business portfolio, aiming for sustainable profit growth and enhanced corporate
value.
In the pharmaceutical business, which is the core business of the Group, although annual drug price revisions and
other factors continue to have an impact, the Group expects earnings to be supported by the increase in minimum
drug prices under the latest drug price revision, growth in obstetrics and gynecology products, overseas business,
and other factors. The Company projects consolidated net sales of 73,000 million yen (a 2.6% increase compared to
the same period last year). Regarding profits, the Company expects operating profit of 6,200 million yen (up 6.3%)
and ordinary profit of 6,100 million yen (up 7.7%), driven by factors such as higher net sales. The Company projects
that profit attributable to owners of parent will be 4,800 million yen (down 11.5% YoY).
(NOTE) The above forecasts have been prepared based on information available as of the announcement date and are subject to various uncertainties. As a result, actual results may differ from this forecast.